-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
RN-18
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/431980-38-0.gif)
| Category | Human immunodeficiency Virus (HIV) |
| CAS | 431980-38-0 |
| Description | RN-18, a selective inhibitor of virion infectivity factor (Vif) APOBEC interactions and HIV-1 replication (IC50= 6 μM in nonpermissive H9 cells), antagonizes Vif function and inhibits HIV-1 replication only in the presence of A3G. |
Product Information
| Synonyms | RN-18; RN 18; RN18; N-(2-methoxyphenyl)-2-(4-nitrophenyl)sulfanylbenzamide; 2-(4-Nitrophenylthio)-N-(2-methoxyphenyl)benzamide; AC1LQ42R; Ambcb6776439 |
| IUPAC Name | N-(2-methoxyphenyl)-2-(4-nitrophenyl)sulfanylbenzamide |
| Molecular Weight | 380.42 |
| Molecular Formula | C20H16N2O4S |
| Canonical SMILES | COC1=CC=CC=C1NC(=O)C2=CC=CC=C2SC3=CC=C(C=C3)[N+](=O)[O-] |
| InChI | 1S/C20H16N2O4S/c1-26-18-8-4-3-7-17(18)21-20(23)16-6-2-5-9-19(16)27-15-12-10-14(11-13-15)22(24)25/h2-13H,1H3,(H,21,23) |
| InChIKey | JKNUDHUHXMELIJ-UHFFFAOYSA-N |
| Boiling Point | 493.6±40.0 °C at 760 Torr |
| Purity | 99.37% |
| Density | 1.36±0.1 g/cm3 |
| Solubility | DMSO: 10 mM |
| Appearance | Light yellow to yellow (Solid) |
| Storage | Store in a cool and dry place (or refer to the Certificate of Analysis). |
| Complexity | 505 |
| Exact Mass | 380.08307817 |
| In Vitro | RN-18 and RN-19 exhibits potent antiviral activity in the nonpermissive H9 and CEM cells but not in MT4 or CEM-SS cells, confirming that the antiviral activity was Vif specific. RN-18 shows the greater potency (IC50=4.5 μM in CEM cells) and specificity (IC50>100 μM in MT4 cells) among the two compounds. In the presence of the inhibitor, RN-18, reverse transcriptase activity in the nonpermissive H9 and CEM cells decreases substantially and in a dose-dependent manner. RN-18 also exhibits antiviral activity in CEM-SS modified to stably express A3G but does not exhibit antiviral activity in the parental CEM-SS cell line. RN-18 antagonizes Vif function and inhibits HIV-1 replication only in the presence of A3G. RN-18 increases cellular A3G levels in a Vif-dependent manner and increases A3G incorporation into virions without inhibiting general proteasome-mediated protein degradation. RN-18 enhances Vif degradation only in the presence of A3G, reduces viral infectivity by increasing A3G incorporation into virions and enhances cytidine deamination of the viral genome. |
| PSA | 112.94000 |
| Target | HIV |
| XLogP3-AA | 4.6 |
